APPLICATION
ANDA209598
TYPE
ANDA
ORIGINAL APPROVAL
2023-03-13
LATEST ACTION
2025-01-29
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
TERIFLUNOMIDEPrescription
TERIFLUNOMIDE 7MG · TABLET · ORAL
TERIFLUNOMIDEPrescription
TERIFLUNOMIDE 14MG · TABLET · ORAL
Approval history
2025-01-29Labeling · Supplement 3 · standardAP
2023-03-13UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.